Filtering by Tag: cancer
Researchers at Queens University Belfast have published findings where a multi-marker panel of 4 proteins (CA125, phosphatidylcholine-sterol aceltransferase, vitamin K-dependent protein Z, and CRP) has the potential to diagnose epithelial ovarian cancer (EOC) one to two years earlier than current methods.
The SpotProfiler is a prime candidate to translate this type of research finding into an easily accessible medical tool for physicians with its multi-marker protein microarray approach.
Resolution Bioscience's blood test was granted a breakthrough device designation by the FDA in May. It is currently being used to help develop a companion liquid biopsy test for Janssen’s PARP inhibitor Zejula (niraparib) drug in patients with metastatic castration-resistant prostate cancer.
CA19-9 is a sugar molecule present on many proteins. It is often elevated in patients with pancreatitis and pancreatic cancer; hence, it has been used for more than 30 years to assess disease burden. Recently, scientists at Cold Spring Harbor Laboratory (CSHL) have found that CA19-9 may actually promote the development of these pancreatic diseases and that blocking CA19-9 could serve as a therapeutic strategy. An antibody drug targeting CA19-9, MVT-5873, is in clinical testing for pancreatic cancer and was acquired by German biotech BioNTech.
Bio-Techne’s urine test, ExoDx Prostate IntelliScore test, tracks down the exosomes and genomic markers released from prostate cancer cells. It is the first liquid biopsy to receive breakthrough status from the FDA for targeting exosomes. The aim of the test is to rule out unnecessary tissue biopsies following the results of a prostate-specific antigen (PSA) test, which can give false positive results.
Proteus Digital Health has launched an oral chemotherapy equipped with its ingestible sensor. The digital pill will be used to treat stage 3 and 4 colorecal cancer patients with capecitabine, and provide feedback to physicians by reporting the time, dose, and type of chemotherapy taken. This gives physicians a better opportunity to intervene if patients are not taking their medication correctly or miss a dose.
CellMax Life’s CMx platform filters out and counts precancer and cancer cells in the bloodstream. It’s FirstSightCRC test was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy. The increases in cell counts also correlates with increases in disease severity. This is a highly sensitive noninvasive testing option for precancer instead of a colonoscopy.
University of Queensland researchers developed a screening tool to inform clinicians if a patient may have cancer through a simple and inexpensive blood test. However, the procedure does not show where the cancerous cells are located and how serious the patient’s condition is. The test uses gold nanoparticles to detect for cancer DNA and the result is a colour change visible to the naked eye.
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
A new study from The Ohio State University found that mailing at-home HPV tests to hard-to-reach women may be a viable approach, one that could be especially helpful in regions such as Appalachia, where access to women’s health care can be limited.
The study, which appears in the journal Sexually Transmitted Diseases, found that almost 80 percent of women who received the kits used them and sent them back to the researchers for testing. About a quarter of them tested positive for a cancer-causing type of HPV.
Quanterix is expanding its blood biomarker testing business into oncology, providing an early access program to its benchtop imager and a new 10-plex assay panel for cancer research and drug development. The product covers more than 50 analytes and allows researchers to develop custom assays, including pharmacokinetic, pharmacodynamic and immunogenicity assays. The benchtop instrument includes a touchscreen interface and high-resolution camera, and requires little maintenance and calibration.
Biodesix has acquired Integrated Diagnostics and its precommercial XL2 lung cancer blood test. The test aims to help physicians rule out the patients that do not need to have a biopsy of a suspicious lung nodule by differentiating benign lung nodules from malignant ones using proteins found in the bloodstream.